Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrocortisone, quantity: 20 mg - tablet, uncoated - excipient ingredients: povidone; magnesium stearate; macrogol 8000; lactose monohydrate; maize starch - indications as at 6 may 1992: hydrocortisone is indicated for replacement therapy in addison's disease or chronic adrenocortical insufficiency secondary to hypopituitarism.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrocortisone, quantity: 4 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; lactose monohydrate; povidone - indications as at 6 may 1992: hydrocortisone is indicated for replacement therapy in addison's disease or chronic adrenocortical insufficiency secondary to hypopituitarism.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrocortisone, quantity: 20 mg - tablet, uncoated - excipient ingredients: povidone; magnesium stearate; macrogol 8000; lactose monohydrate; maize starch - indications as at 6 may 1992: hydrocortisone is indicated for replacement therapy in addison's disease or chronic adrenocortical insufficiency secondary to hypopituitarism.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrocortisone, quantity: 4 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; lactose monohydrate; povidone - indications as at 6 may 1992: hydrocortisone is indicated for replacement therapy in addison's disease or chronic adrenocortical insufficiency secondary to hypopituitarism.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 336 mg (equivalent: ranitidine, qty 300 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; maize starch; pregelatinised maize starch; lactose monohydrate; magnesium stearate; povidone - inoperable prostatic carcinoma. to suppress 'flare' with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - bicalutamide, quantity: 50 mg - tablet, film coated - excipient ingredients: macrogol 400; lactose monohydrate; povidone; titanium dioxide; hypromellose; magnesium stearate; sodium starch glycollate type a - treatment of advanced prostate cancer in combination with lhrh agonist therapy. prevention of disease flare associated with the use of lhrh agonists.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - adenosine, quantity: 6 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - therapeutic indications: adenosine viatris is indicated for the rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white syndrome). diagnostic indications: adenosine viatris is indicated as an aid to diagnosis of broad or narrow qrs complex supraventricular tachycardias. although adenosine viatris is not effective in converting atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of av conduction helps diagnosis of atrial activity. in this respect adenosine should be used as an adjunct to, but not a replacement for, clinical and ecg observations. it should be used only when, despite all diagnostic attempts, doubt still persists. adenosine viatris can also be used for improved diagnostic sensitivity of intracavity electrophysiological investigations.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - terbinafine hydrochloride, quantity: 281.25 mg (equivalent: terbinafine, qty 250 mg) - tablet, uncoated - excipient ingredients: croscarmellose sodium; purified talc; colloidal anhydrous silica; magnesium stearate; povidone; microcrystalline cellulose - treatment in adults of ringworm (tinea corporis, tinea cruris and tinea pedis) due to infection caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidermophyton floccosum, where oral therapy is considered appropriate owing to the site, severity or extent of the infection, and the infection is not responsive to topical therapy. onychomycosis in adults (fungal infection of the nail) caused by dermatophyte fungi.